New data demonstrate Guardant Infinity’s high precision
in monitoring for early and long-term response to therapy
and disease progression
Greater precision than genomics only,*
providing a
clearer view of therapy response2
Better stratify patients with improved PFS
compared with genomic variant-based methods1
*3x higher precision estimated in comparison to response tracking with 3 somatic mutations for a representative sample at 0.1% tumor fraction and typical input amount.
CH, clonal hematopoiesis; PFS, progression-free survival.
QUANTIFY CANCER
Guardant Infinity’s methylation-based monitoring delivers accuracy while overcoming challenges of genomic variant-based methods.¹
20% increase in quantifiable rate compared
with genomic-only
approaches after excluding
variants confirmed as CH1
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma